Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data PureTech Health plc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
20.7
9.81
11.8
17.4
15.6
3.33
4.83
Research and development
77.4
85.8
81.9
110
152
96.2
69.5
Operating income
-104
-135
-120
-150
-198
-146
-136
Interest expense
-0.03
2.58
2.95
4.77
3.94
3.42
1.73
Interest income
3.36
4.36
1.18
0.21
5.8
16
22.7
Pre-tax income
-68.4
478
19
-59
-92.8
-36.1
23.8
Income tax
2.22
112
14.4
3.76
-55.7
30.5
-4.01
Net income to minority interests
-27
-55.1
-1.42
-2.15
13.3
-0.93
-25.7
Net income
-43.7
421
5.99
-60.6
-50.4
-65.7
53.5
EBITDA
-143
-189
-141
-133
EPS, basic
-0.16
1.49
0.02
-0.21
-0.18
-0.24
0.21
EPS, diluted
-0.16
1.44
0.02
-0.21
-0.18
-0.24
0.21
Balance sheet
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
117
132
404
466
150
191
281
Receivables
1.98
2.56
3.17
11.9
2.38
1.52
Total current assets
169
414
502
386
347
386
Property, plant and equipment
21.5
22.8
26.8
23
9.54
7.07
Lease right-of-use assets
10.4
22.4
20.1
17.2
14.3
9.83
8.06
Intangible assets
0.63
0.9
0.99
0.83
0.91
Total assets
941
990
946
703
694
603
Accounts payable
19.8
21.8
35.8
54.8
44.1
27
Total current liabilities
139
181
226
96.9
51.4
41.4
Lease liabilities
34.9
32.1
29
24.2
18.3
14.7
Total liabilities
291
336
362
155
236
195
Total debt
0
0
14.8
15.1
15.4
0
Paid-in capital
288
289
289
290
290
290
Retained earnings
254
260
200
150
83.8
32.5
Shareholders' equity
668
670
594
542
464
415
Minority interests
-17.6
-16.2
-9.37
5.37
-5.84
-6.77
Total equity
168
650
654
584
548
458
408
Total liabilities and equity
941
990
946
703
694
603
Cash flow statement
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
Net income
-70.7
366
4.57
-62.7
-37.1
-66.6
27.8
Depreciation and amortization
7.29
8.89
4.93
3.57
Cash from operations
-72.8
-98.2
-132
-158
-179
-106
-134
Capital expenditures
-4.37
-12.1
-5.17
-5.57
-2.18
-0.07
-0.01
Cash from investing
-39.6
63.7
364
197
-107
69
241
Stock issued
152
0
0
Share buybacks
-0.04
0
0
Cash from financing
157
49.9
38.9
22.7
-29.8
78.1
-17
Exchange rate effect
-0.04
-0.1
0
0
Net change in cash
44.4
15.3
272
61.8
Free cash flow
-77.2
-110
-137
-164
-181
-106
-134
Interest paid
0
2.5
2.65
3.38
3.37
1.7
1.3
Income taxes paid
0
0
20.7
27.8
20.7
0.15
37.9
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. Valuation uses the share price of $15.15 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-2,819.0%
Operating income / revenue.
EBITDA margin
-2,745.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
492.4%
Pre-tax income / revenue.
Net margin
1,108.0%
Net income / revenue.
FCF margin
-2,783.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-2,783.0%
Cash from operations / revenue.
Effective tax rate
-16.9%
Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)
12.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
8.3%
Net income / average total assets.
Return on invested capital (ROIC)
-52.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
1,439.0%
Research and development expense / revenue.
Capex / revenue
0.2%
Capital expenditures / revenue.
D&A / revenue
74.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
45.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-34.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-13.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income CAGR, 5y
-33.8%
Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS CAGR, 5y
-32.0%
Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-10.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-11.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-9.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-13.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-14.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-8.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
9.33x
Current assets / current liabilities.
Quick ratio
6.82x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.78x
(Cash + short-term investments) / current liabilities.
Free cash flow / net income, when net income is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$0.21
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
$0.21
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$3.66B
Share price x shares outstanding.
Enterprise value
$3.38B
Market cap + total debt - cash - short-term investments.
P/E
68.4x
Market cap / net income. Only when net income is positive.
P/S
758x
Market cap / revenue.
P/B
8.83x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
8.83x
Market cap / tangible book value, when positive.
EV/Sales
700x
Enterprise value / revenue.
FCF yield
-3.7%
Free cash flow / market cap.
Earnings yield
1.5%
Net income / market cap (the inverse of P/E).
What was PureTech Health plc's revenue in fiscal 2024?
PureTech Health plc reported revenue of $4.8M for fiscal 2024, 45% higher than the year before.
Was PureTech Health plc profitable in fiscal 2024?
Yes. Net income was $53.5M, a net margin of 1,108.3%.
How much free cash flow did PureTech Health plc generate in fiscal 2024?
Cash from operations of $134.4M minus capital expenditures of $11.0K left free cash flow of -$134.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.